Eli Lilly overtakes Novo Nordisk in ex-U.S. GLP-1 share

Q1 overseas Mounjaro revenue reached $8.7B, beating consensus and allowing Eli Lilly to overtake Novo Nordisk in non-U.S. GLP-1 market share for the first time. In oral GLP-1s, however, Novo's Wegovy pill launched first in January and appears to be seeing faster early uptake than Lilly's Foundayo, or orforglipron, launched in April.